Does recombinant human erythropoietin affect plasma lipids in hemodialysis patients?

被引：4

作者：

Cengiz, K

机构：

[1] Ondokuz Mayis University, Faculty of Medicine, Department of Nephrology, Samsun

来源：

NEPHRON | 1996年 / 74卷 / 04期

关键词：

D O I：

10.1159/000189484

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：731 / 732

页数：2

共 5 条

[1] BRENNER BM, 1991, KIDNEY, V2, P2238
[2] BENEFITS AND RISKS OF PROTRACTED TREATMENT WITH HUMAN RECOMBINANT ERYTHROPOIETIN IN PATIENTS HAVING HEMODIALYSIS
CASATI, S
PASSERINI, P
CAMPISE, MR
GRAZIANI, G
CESANA, B
PERISIC, M
PONTICELLI, C
[J]. BMJ-BRITISH MEDICAL JOURNAL, 1987, 295 (6605): : 1017 - 1020
[3] BLOOD LIPID PROFILE IN HEMODIALYSIS-PATIENTS TREATED WITH HUMAN ERYTHROPOIETIN
MAT, O
STOLEAR, JC
GEORGES, B
[J]. NEPHRON, 1992, 60 (02): : 236 - 237
[4] PRATA MM, 1990, NEPHROL DIAL TRANSPL, V15, P47
[5] EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN ON NUTRITIONAL-STATUS AND PLASMA-LIPIDS IN UREMIC PATIENTS
VIRON, B
DONSIMONI, R
MICHEL, C
ALKHAYAT, R
MIGNON, F
[J]. NEPHRON, 1992, 60 (02): : 249 - 249